u/border_paperwork

there is no safe bracket, there are only brackets that get looked at more. and nobody publishes the thresholds.

The carrier pattern is real and it is not mysterious. Different carriers have different customs brokerage arrangements and different thresholds at which they refer an item rather than clear it. You are not seeing a country policy, you are seeing a broker's risk appetite.

Which is why "research-use documentation" is not a magic word. It is a document that a broker may or may not be interested in, depending on their process.

Posted a question here with my address in the screenshot. A mod removed it within minutes, which I appreciated.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

Address redacted from the screenshot above. Post the wording of the notice, never the header.

Disagree with the framing. Regain is the documented outcome after discontinuation; calling it a personal failure is both wrong and corrosive.

Declared value and product description are chosen by the shipper. Asking what they use is a legitimate pre-order question and the answer tells you how routine this is for them.

How long has it been sitting, and at which stage?

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why.

Adding the standing caveat — unapproved compound, research material is not for human use.

What does the notice actually say, in its own words?

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

This is the sentence that reframes the whole board.

Agreed — and the exposure lag means the first fortnight tells you almost nothing.

Australia and New Zealand are separate systems and get conflated weekly

That delay was at clearance, not with the carrier. The lane table separates them for exactly this reason.

Is this a hold, a request for information, or a seizure notice?

research-use-only labelling is not a customs category

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

Left up. It names both countries and quotes the notice, which is exactly what makes these threads useful.

Country added to the title. Without it the answers will be confidently wrong.

independent testing on this compound is very thin

Preparing to stop, as described by people here who have done it.

Write down where you are first: dose, date, weight, waist, and an honest note about how appetite feels. That page is what makes the following six months interpretable rather than a fog of impressions.

Decide in advance what you are watching for and over what period — appetite in the first month, weight over three, and a specific threshold at which you would want to revisit the decision. Have the conversation with a clinician before rather than after.

None of that is a schedule. It is a way of arriving at whatever happens next with information rather than with a vague sense of how it is going.

Address redacted from the screenshot above. Post the wording of the notice, never the header.

Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.

Appetite is the proximal effect and weight is the lagging integrated outcome, which is why watching appetite gives you an earlier and more honest signal.

How fast was the escalation in that protocol?

Why regional stock keeps coming up in every thread on this board.

If the line you want is held in a warehouse in your own country, your order is a domestic shipment. There is no import event, no clearance stage and no notice to manage. That is not a workaround; it is a different transaction.

So the useful pre-order question is which lines a supplier actually holds regionally rather than drop-ships from origin. It is one email, the answer is usually a list, and for anybody who has spent a fortnight watching a tracking page it reframes the whole problem.

interval stretching is the most commonly described approach here

Agreed that returning later is common and it is treated here as ordinary rather than as a defeat.

Correction: that study measured regain after discontinuation, not loss of effect during treatment. Very different findings.

Regained most of it over a year and spent that year assuming it was my fault. It was not; it is what the literature describes.

Address redacted from the screenshot above. Post the wording of the notice, never the header.

Nothing on this board is a taper schedule, and no member can write one for another. What can be shared is what people watched and what they observed.

say which state only if it matters, but always say which country

The honest evidence position, written out so this board does not drift.

Phase 2 data exists in a specific, biopsy-characterised population, with a slow protocol escalation and tolerability tables worth reading in full. Nothing containing this compound is approved by any regulator anywhere. Research-use-only material is not approved for human use.

Independent purity results across this entire site number in the low single figures. That means nobody here — including the people who post most confidently — has a basis for statements about batch-to-batch consistency. If you test something, post it; the log is the only thing that will change that position.

the weight numbers are secondary to what this is being developed for

stretching to ten days then twelve is the pattern people report

What the evidence says about stopping, written plainly because the framing does real damage.

Withdrawal studies across this class consistently show substantial regain after discontinuation. Appetite typically returns first, well before weight changes. This is a finding about the pharmacology of a chronic condition, in the same way that blood pressure rises again when an antihypertensive is stopped.

People on this board quit in shame over an entirely predictable result, and then avoid coming back because they have interpreted it as a personal failure. It is not. Knowing that in advance is the single most useful thing this board can offer anybody planning to stop.

Stopped for cost reasons. Appetite came back at about week 9, well before the scale moved, exactly as this board said it would.

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

do not post your own address details when asking

rina_bergstrom is right that regional stock is the structural answer rather than a trick.